Michael E. Farkouh, MD; Jeff D. Lang, MD; David L. Sackett, MD, MSc
Farkouh ME, Lang JD, Sackett DL. Thrombolytic Agents: The Science of the Art of Choosing the Better Treatment. Ann Intern Med. 1994;120:886-888. doi: 10.7326/0003-4819-120-10-199405150-00011
Download citation file:
Published: Ann Intern Med. 1994;120(10):886-888.
The current dispute about whether the thrombolytic agent of choice for patients with suspected heart attacks should be tissue plasminogen activator (tPA) or streptokinase is succulent. It invokes arguments across the spectrum of health research, from bench to bedside to cost–benefit. Its combatants (and many of their defenders and detractors) are informed, articulate, and proud. The financial stakes are colossal. Reputations and fortunes are on the line. There is enough science and show-biz for every interest and taste. Somewhere, William Osler and H. L. Mencken are exchanging winks.
But how ought a clinician decide which of these two treatments, each with its competing claims for superiority, is the best one for her to use in her practice? There should be a science to the art of making such clinical judgments, and it should go beyond special pleading, polemics, and appeals to authority. What are some of the elements of that science? How might they apply to the current controversy?
Learn more about subscription options.
Register Now for a free account.
Cardiology, Emergency Medicine, Neurology, Acute Coronary Syndromes, Coronary Heart Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only